Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 98,888 Shares

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 98,888 shares of Verona Pharma stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $5.01, for a total value of $495,428.88. Following the completion of the sale, the chief executive officer now directly owns 15,078,624 shares in the company, valued at approximately $75,543,906.24. This represents a 0.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

David Zaccardelli also recently made the following trade(s):

• On Monday, December 2nd, David Zaccardelli sold 3,200 shares of Verona Pharma stock. The shares were sold at an average price of $5.00, for a total value of $16,000.00.
• On Wednesday, November 27th, David Zaccardelli sold 23,240 shares of Verona Pharma stock. The shares were sold at an average price of $5.00, for a total value of $116,200.00.
• On Monday, November 11th, David Zaccardelli sold 2,400 shares of Verona Pharma stock. The stock was sold at an average price of $5.00, for a total transaction of $12,000.00.
• On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The shares were sold at an average price of $4.39, for a total transaction of $413,292.16.
• On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $205,369.44.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $1,076,533.92.

Verona Pharma Stock Down 1.2 %

NASDAQ VRNA opened at $38.66 on Wednesday. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. The company has a market cap of $3.09 billion, a price-to-earnings ratio of -20.14 and a beta of 0.46. The company has a 50 day moving average of $35.03 and a 200-day moving average of $25.79. Verona Pharma plc has a 1-year low of $11.39 and a 1-year high of $40.76.

Verona Pharma (NASDAQ:VRNA) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.12). The business had revenue of $5.62 million during the quarter, compared to analysts’ expectations of $2.31 million. During the same period in the previous year, the company earned ($0.18) earnings per share. On average, equities research analysts expect that Verona Pharma plc will post -2.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Verona Pharma

Institutional investors and hedge funds have recently bought and sold shares of the company. Eventide Asset Management LLC raised its position in shares of Verona Pharma by 359.6% in the 3rd quarter. Eventide Asset Management LLC now owns 2,425,846 shares of the company’s stock valued at $69,792,000 after buying an additional 1,898,065 shares in the last quarter. Maverick Capital Ltd. raised its position in Verona Pharma by 74.2% during the second quarter. Maverick Capital Ltd. now owns 3,092,807 shares of the company’s stock valued at $44,722,000 after purchasing an additional 1,316,998 shares in the last quarter. Loomis Sayles & Co. L P bought a new stake in Verona Pharma during the third quarter worth $31,966,000. Candriam S.C.A. acquired a new stake in shares of Verona Pharma in the 2nd quarter valued at $11,177,000. Finally, Jennison Associates LLC increased its stake in shares of Verona Pharma by 54.3% in the 3rd quarter. Jennison Associates LLC now owns 1,740,886 shares of the company’s stock valued at $50,085,000 after purchasing an additional 612,854 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on VRNA. Truist Financial upped their price objective on shares of Verona Pharma from $38.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Wells Fargo & Company raised their price objective on shares of Verona Pharma from $50.00 to $64.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Canaccord Genuity Group upped their target price on Verona Pharma from $37.00 to $44.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Finally, HC Wainwright lifted their price target on Verona Pharma from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $43.83.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.